Genmab A/S: Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma

Related Keywords

Japan ,Lugano ,Ticino ,Switzerland ,Netherlands ,Copenhagen ,Køavn ,Denmark ,Tokyo ,Chicago ,Illinois ,United States ,Germany ,New Jersey ,American ,David Freundel ,Judith Klimovsky ,Andrew Carlsen ,Gewinn Nur ,Product Communications ,Exchange Commission ,European Medicines Agency ,International Conference On Malignant Lymphoma ,Meeting Library ,Twitter ,Access Library ,Abbvie Biotechnology Ltd ,American Society Of Clinical Oncology ,Ministry Of Health ,European Hematology Association ,Clinical Oncology ,Annual Meeting ,Hematology Association ,Executive Vice President ,Chief Development Officer ,International Conference ,Malignant Lymphoma ,World Evidence ,Marketing Authorization Application ,European Medicines ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Prescribing Information ,Medication Guide ,Media Release ,Annual Report ,Y Shaped Genmab ,Abbvie Biotechnology ,Senior Director ,Vice President ,Investor Relations ,Genmab ,Nnounces ,Multiple ,Abstracts ,Resented ,Society ,Linical ,Ncology ,Disco ,Nnual ,Meeting ,European ,Hematology ,Association ,Congress ,